Tokyo-based venture capital firm Axil Capital has led a $9.8-million Series A funding in Luca Science, a Japanese preclinical biopharmaceutical company that focuses on the discovery of mitochondria therapy to treat diseases and injuries.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
